Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of regorafenib after sorafenib in hepatocellular carcinoma
NL-OMON40509Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Started Nov 2014; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON40509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40509.